Ashkan Adibi/LinkedIn
May 23, 2025, 08:33
Ashkan Adibi: Exceptional Response in mRCC Through Precision-Guided Immunotherapy Rechallenge with Temsirolimus and Bevacizumab
Ashkan Adibi, PhD Candidate of Cancer Genetics at Oncology Institute of Istanbul Medical University, shared a post on LinkedIn:
“We are thrilled to share that our latest paper, ‘Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Recchallenge with Temsirolimus and Bevacizumab,’ has been published in the Journal of Immunotherapy and Precision Oncology!
Initially, the patient did not respond to dual immunotherapy with nivolumab and ipilimumab combined with the low-dose PARP inhibitor niraparib, and experienced immune-related adverse events. Following disease progression, a second comprehensive genomic profiling (CGP) was performed, resulting in a changed treatment plan.
Ultimately, she transitioned to temsirolimus plus bevacizumab, along with a rechallenge of immunotherapy using pembrolizumab. This combination resulted in a complete radiographic and molecular response. This study underscores the increasing significance of precision oncology and molecular tumor boards (MTBs) in developing personalized cancer treatment plans. Furthermore, the study suggests that mTOR inhibitors may enhance the efficacy of immunotherapy for certain patients based on genomic findings.
This study highlights the potential of precision-guided strategies to overcome treatment resistance and optimize patient outcomes. It is a testament to the evolving landscape of personalized medicine, and I am proud to have played a part in it.
I am grateful to my colleagues Ünal Metin Tokat , Esranur Aydın, Eylul Ozgu, and Şevval Nur Bilgiç, PhD as well as our professor, Prof. Dr. Mutlu Demiray , who made this case possible, and to Nalan Babacan.”
Title: Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab
Authors: Ashkan Adibi, Ünal Metin Tokat, Esranur Aydın, Eylül Özgü, Şevval Nur Bilgiç, Nalan Akgül Babacan, Onur Tutar, Razelle Kurzrock, Mutlu Demiray
You can read the Full Article on Journal of Immunotherapy and Precision Oncology
More posts featuring Bevacizumab.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 23, 2025, 08:18
May 23, 2025, 07:59
May 23, 2025, 07:53
May 23, 2025, 07:43
May 23, 2025, 07:36
May 23, 2025, 07:11
May 23, 2025, 07:02